Author:
Ishii Toshiyuki,Iwasawa Shunichiro,Kurimoto Ryota,Maeda Akemi,Takiguchi Yuichi,Kaneda Makoto
Publisher
Public Library of Science (PLoS)
Reference31 articles.
1. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;M Maemondo;The New England journal of medicine,2010
2. Erlotinib in previously treated non-small-cell lung cancer;FA Shepherd;The New England journal of medicine,2005
3. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors;S Segaert;Annals of oncology,2005
4. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial;VA Miller;The Lancet Oncology,2012
5. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan;Y Ohe;Annals of oncology,2007
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献